Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report)’s stock price rose 11.6% on Thursday . The company traded as high as $17.00 and last traded at $15.44. Approximately 409,503 shares were traded during mid-day trading, an increase of 717% from the average daily volume of 50,104 shares. The stock had previously closed at $13.83.
Neoleukin Therapeutics Stock Performance
The company has a market capitalization of $145.11 million, a price-to-earnings ratio of -4.96 and a beta of 1.11. The business’s 50 day moving average price is $14.00 and its two-hundred day moving average price is $24.46.
Neoleukin Therapeutics Company Profile
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
Featured Articles
- Five stocks we like better than Neoleukin Therapeutics
- Dividend Payout Ratio Calculator
- 2 Strong Utilities Plays With Booming Earnings and Room to Grow
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Why Smart Investors Don’t Panic in Election Season
- What Are Dividend Champions? How to Invest in the Champions
- Now Is the Time to Buy ServiceNow—The Rebound Is Real
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
